Physician profile
John N Chafos
NPI 1871673830
$1,734.50
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $255 · 2021: $339 · 2022: $302 · 2023: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $146.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $405.67 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $136.59 | 2019-2023 | |
| Glaxosmithkline, LLC. | $114.91 | 2019-2021 | |
| Allergan, INC. | $111.52 | 2019-2020 | |
| Abbvie INC. | $108.73 | 2021-2023 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $101.03 | 2019-2023 | Farxiga |
| Genentech USA, INC. | $82.38 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $78.40 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.51 | 2019-2021 | |
| Amarin Pharma, INC. | $55.87 | 2019-2021 | |
| Amgen INC. | $54.56 | 2021-2022 | |
| Almatica Pharma LLC | $43.64 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $42.82 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $40.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $33.37 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $27.26 | 2022 | |
| Abbott Laboratories | $26.90 | 2022 | |
| Lilly USA, LLC | $25.45 | 2020 | |
| Exact Sciences Corporation | $21.36 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $20.41 | 2023 | Veozah |
| Kowa Pharmaceuticals America, INC. | $15.00 | 2022 | |
| Horizon Therapeutics Plc | $14.27 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.11 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.96 | 2019 | |
| Nabriva Therapeutics, Plc | $13.42 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.18 | 2022 | |
| Shire North American Group INC | $12.94 | 2019 | |
| Indivior INC. | $12.19 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chafos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.